The incidence of type 1 diabetes, which currently affects 29 million adults worldwide, is rising. In the United States, the number of patients with type 1 diabetes who are younger than 20 years of age may triple within 30 years. Less than one-third of adults with type 1 diabetes achieve a glycated hemoglobin level lower than 7.0%, and most are overweight or obese.
Patients with type 1 diabetes also face risks of complications or death from severe hypoglycemia and diabetic ketoacidosis. The ideal treatment for type 1 diabetes should enable patients to maintain a glycated hemoglobin level lower than 7.0% without weight gain or an increased risk of hypoglycemia and diabetic ketoacidosis. Except for nasal spray of Insulin or insulin pill no tablet or oral medicine is present to treat Type 1 diabetes but Sotagliflozin (LX4211) is a new oral inhibitor of sodium-glucose cotransporters 1 and 2…
